my.bionity.com
With an accout for my.bionity.com you can always see everything at a glance – and you can configure your own website and individual newsletter.
We are a genomics based drug discovery company, that has drug discovery programs based on proprietary disease modifying drug targets. Our vision is to bring novel drugs to the market in selected diseases areas for which there is a need for effective and safe medicines. We focus on developing drugs t more
As the service division of Galapagos, BioFocus DPI offers a full suite of target-to-drug discovery products and services. Our aim is to expand our partners’ drug pipeline by accelerating the gene-to-candidate discovery process. We achieve this by offering a biologically-focused discovery platform more
Galapagos NV announced that its service division BioFocus and Ono Pharmaceutical Co., Ltd. have signed a new collaboration agreement, focused on discovering novel drugs in the field of CNS disorders. Under the new agreement, BioFocus will use its drug discovery platform to deliver leads and clinica more
Galapagos’ service companies, BioFocus and Argenta, announced they have entered into a multi-year collaboration agreement with AstraZeneca to find new compounds against key targets of interest to AstraZeneca’s research programs in respiratory and inflammatory diseases. Under the terms of the collabo more
Almirall, S.A. announced that it has formed a research alliance with BioFocus, an affiliate from Galapagos NV.The three-year alliance is aimed at delivering drug development candidates directed to a key respiratory target of interest to Almirall. Under the terms of the collaboration, BioFocus will more
Galapagos NV (Galapagos) is a publicly held research focused biopharmaceutical company. It is engaged in discovery and development of disease modifying drugs. The company develops GLPG0259 that targets protein kinase MAPKAPK5, as its leading drug candidate for the under initial stages of clinical tr more
Galapagos NV (Galapagos) is Belgium based health care pharmaceutical company. The company is involved in discovery and manufactures of disease modifying drugs. It develops GLPG0259 which aim protein kinase MAPKAPK5, as its leading drug candidate for the under initial stages of clinical trials. The more
Protein Kinase 2010: Signalling Success 4 th SCI-RSC Symposium on Kinase Inhibitor Design +44 1799 533 500 email us Register here for our mailing list Registration to this event is FREE Home Offerings Careers About us Contact us News & events Contact us BioFocus DPI e-update summer 09 BioFocus e-upd more
Home What CellAura Does What's New News Events Catalogue of Reagents Custom Ligand Development New Product Development Resources Contact Us Events Upcoming Events There are currently no event Past Events Cambridge Healthtech Institute - High Content Analysis 2009 Attended by over 400 delegates, wi more
Protein Kinase 2010: Signalling Success 4 th SCI-RSC Symposium on Kinase Inhibitor Design +44 1799 533 500 email us Register here for our mailing list Registration to this event is FREE Home Offerings Careers About us Contact us News & events Contact us BioFocus DPI e-update summer 09 BioFocus e-upd more
Watchlist
This is where you can add this topic to your personal favourites
Über CHEMIE.DE
CHEMIE.DE Information Service GmbH runs specialist scientific internet portals. The secret to our success? We are familiar with what we publish.
Advertising at CHEMIE.DE
Our advertising formats support you in getting your message across to a clearly defined target audience.
© 1997-2013 CHEMIE.DE Information Service GmbH, All rights reserved
Netmeeting
